Donald P. McDonnell
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (16)
Endocrine therapy has proven to be beneficial for patients with estrogen receptor (ER)–positive, HER2-negative (ER+/HER2−) breast cancer; however, de novo or acquired resistance remains a major clinical challenge. Upon progression, many of the cancers continue to be ER dependent, highlighting the opportunities for novel ER-targeting therapies. Fulvestrant, a selective ER degrader (SERD) that antagonizes and degrades ER simultaneously, has demonstrated activity in ER+/HER2− breast cancers the ability to overcome endocrine resistance. Fulvestrant has limitations, including challenging administration by intramuscular injection and poor bioavailability, resulting in suboptimal drug exposure; hence, several next-generation oral SERDs with improved drug properties have been developed and are currently being evaluated in the clinic for their therapeutic benefit. In this study, we describe the discovery of ZN-c5, an orally bioavailable SERD with favorable pharmacokinetic properties and potent activities against both wild-type and mutant ER. In vivo studies showed that ZN-c5 treatment resulted in significant tumor growth inhibition in a variety of breast cancer models and patient-derived xenograft models that harbor ESR1 mutations. Combination with CDK4/6 inhibitors or PI3K pathway inhibition enhanced antitumor effects compared with single-agent alone. ZN-c5 also demonstrated bone-protective effect as observed in a mouse osteoporosis model. These data support the clinical utility of ZN-c5 as monotherapy and as a combination therapy for patients with ER+/HER2− breast cancers. Although encouraging plasma exposure and tolerability have been observed for ZN-c5 in patients, further studies are needed to optimize its therapeutic efficacy.
Year:
2026
Purpose: BMS-986365, a heterobifunctional androgen receptor (AR) ligand-directed degrader, was designed as a potent cereblon-dependent degrader and competitive antagonist of the AR to overcome resistance to AR pathway inhibition (ARPI) in metastatic prostate cancer. Experimental Design: The in vitro impact of BMS-986365–induced AR degradation on AR activity and prostate cancer cell proliferation was evaluated. Intrinsic agonistic and antagonist activities of BMS-986365 were assessed. The in vivo antitumor activity of BMS-986365 was compared with enzalutamide in multiple cell line– or patient-derived prostate cancer models. Results: BMS-986365 is a potent, rapid, and selective degrader of AR wild-type (WT) and most of the clinically relevant mutants. Degradation of both WT and mutant AR is the key driver of BMS-986365 efficacy, with additional antagonism of residual AR activity enabled through occupancy of its ligand-binding domain. Compared with enzalutamide, BMS-986365 more efficiently inhibits AR target gene transcription and AR-dependent proliferation of prostate cancer cell lines. Whereas enzalutamide increased AR protein in metastatic castration-resistant prostate cancer (CRPC) models, BMS-986365 maintained low levels of AR protein despite increased AR transcript levels. In vivo, BMS-986365 demonstrated on-target activity, degrading AR, suppressing AR signaling, and inhibiting growth in validated cell line– and patient-derived xenograft models of castration-sensitive prostate cancer and advanced and/or therapy-resistant CRPC. Clinically, BMS-986365 reduced PSA in patients with metastatic CRPC after ARPI, including patients with WT AR. Conclusions: The preclinical observations, coupled with clinical data, strongly support the potential for BMS-986365 to overcome ARPI-resistant disease regardless of AR mutational status. These findings establish BMS-986365 as a first-in-class dual AR degrader and competitive antagonist, likely to emerge as an important tool in the armamentarium to treat prostate cancer. See related commentary by Nyquist and Nelson, p. 13
Year:
2026
The estrogen receptor (ER or ERα) remains the primary therapeutic target for luminal breast cancer, with current treatments centered on competitive antagonists, receptor downregulators, and aromatase inhibitors. Despite these options, resistance frequently emerges, highlighting the need for alternative targeting strategies. We discovered a novel mechanism of ER inhibition that targets the previously unexplored interface between the DNA-binding domain (DBD) and ligand-binding domain (LBD) of the receptor. Through computational screening and functional assays, we identified mitoxantrone (MTO), an FDA-approved topoisomerase II inhibitor, as a specific ligand for this DBD–LBD interface. Comprehensive biophysical, biochemical, and cellular analyses demonstrate that MTO binding induces distinct conformational changes in the ER, triggering rapid cytoplasmic redistribution and proteasomal degradation through mechanisms independent of its DNA damage activity. Critically, MTO effectively inhibits constitutively active ER mutants (Y537S and D538G) associated with endocrine therapy resistance, suppressing both wild-type and mutant ER-dependent gene expression and tumor growth more potently than fulvestrant in cellular and xenograft models. These findings establish the DBD–LBD interface as a druggable allosteric site that can overcome conventional resistance mechanisms, providing a new therapeutic paradigm for targeting nuclear receptor function through disruption of interdomain communication rather than hormone-binding competition.
Year:
2026
Breast cancer remains the most commonly diagnosed malignancy among women worldwide. While breast cancer treatment outcomes have improved in recent years, there remains an unmet medical need for therapeutics that can be used with curative intent in the most aggressive breast cancer subtypes and for those cancers that have metastasized. In recent years, the success of T-cell-based therapies and other technologies that boost antitumor activities of immune cells have increased interest in using natural killer (NK) cell-based immunotherapies to treat solid tumors. These innate lymphoid cells can identify and eliminate tumor cells through their intrinsic cytotoxic activities and their ability to modulate the immune response through cytokine production. Owing to their lack of T-cell receptors, NK cells can also be used in the allogeneic setting, and strategies to develop and establish NK cells as therapeutics in breast cancer are currently being explored. In this review, we describe NK cell biology as it relates to breast cancer pathobiology and treatment outcomes and discuss how NK cell biology can be exploited and manipulated in the development of new therapeutics for breast cancer. Additionally, we review the role of estrogens in regulating NK cell activity and discuss how endocrine therapies targeting the estrogen receptor signaling axis could be employed as an approach to increase tumor immunity and the efficacy of NK-cell-directed immunotherapies.
Year:
2025
Year:
2025
Cancer cells exploit a mesenchymal-like transcriptional state (MLS) to survive drug treatments. Although the MLS is well characterized, few therapeutic vulnerabilities targeting this program have been identified. In this study, we systematically identify the dependency network of mesenchymal-like cancers through an analysis of gene essentiality scores in ∼800 cancer cell lines, nominating a poorly studied kinase, PKN2, as a top therapeutic target of the MLS. Coessentiality relationships, biochemical experiments, and genomic analyses of patient tumors revealed that PKN2 promotes mesenchymal-like cancer growth through a PKN2−SAV1−TAZ signaling mechanism. Notably, pairing genetic PKN2 inhibition with clinically relevant targeted therapies against EGFR, KRAS, and BRAF suppresses drug resistance by depleting mesenchymal-like drug-tolerant persister cells. These findings provide evidence that PKN2 is a core regulator of the Hippo tumor suppressor pathway and highlight the potential of PKN2 inhibition as a generalizable therapeutic strategy to overcome drug resistance driven by the MLS across cancer contexts. Significance: This work identifies PKN2 as a core member of the Hippo signaling pathway, and its inhibition blocks YAP/TAZ-driven tumorigenesis. Furthermore, this study discovers PKN2−TAZ as arguably the most selective dependency of mesenchymal-like cancers and supports specific inhibition of PKN2 as a provocative strategy to overcome drug resistance in diverse cancer contexts. See related commentary by Shen and Tan, p. 458
Year:
2025
-Supplemental Figure 1: Identification of a mesenchymal-like cancer dependency network. - Supplemental Figure 2: TAZ is a core dependency of mesenchymal-like cancer. - Supplemental Figure 3: PKN2 kinase activity inhibits MST1/2. - Supplemental Figure 4: PKN2 promotes resistance to oncogene-therapy induced resistance.
Year:
2025
- Table 1: Pearson Correlation Analysis of ssGSEA EMT Enrichment score vs CRISPR gene dependency score for all solid tumor cell lines in DepMap, excluding sarcomas - Table 2: Pearson Correlation Analysis of ssGSEA EMT Enrichment score vs CRISPR gene dependency score and ssGSEA EMT Enrichment score vs mRNA Expression for all solid tumor cell lines in DepMap, excluding sarcomas - Table 3: Results of the Quantitative Phosphoproteomics experiment of Kinase Active (KA) vs Kinase Dead (KD) PKN2 expressing 293FT cells - Table 4: Candidate list of direct PKN2 substrates -Table 5: Correlation Analysis of ssGSEA YAP/TAZ Enrichment score vs Protein Abundance for all patient tumors in CPTAC - Table 6: Correlation Analysis of ssGSEA YAP/TAZ Enrichment score vs Phosphoprotein Abundance for all patient tumors in CPTAC - Table 7: Substrate Signatures used for CPTAC Kinase Enrichment Analysis
Year:
2025
Triple-negative breast cancers (TNBC) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early-stage localized TNBC, the rate of distant recurrence remains high, and long-term survival outcomes remain poor. In a search for new therapeutic targets for this disease, we observed that elevated expression of the serine/threonine kinase calcium/calmodulin (CaM)-dependent protein kinase kinase 2 (CaMKK2) is highly correlated with tumor invasiveness. In validation studies, genetic disruption of CaMKK2 expression or inhibition of its activity with small molecule inhibitors disrupted spontaneous metastatic outgrowth from primary tumors in murine xenograft models of TNBC. High-grade serous ovarian cancer (HGSOC), a high-risk, poor prognosis ovarian cancer subtype, shares many features with TNBC, and CaMKK2 inhibition effectively blocked metastatic progression in a validated xenograft model of this disease. Mechanistically, CaMKK2 increased the expression of the phosphodiesterase PDE1A, which hydrolyzed cyclic guanosine monophosphate (cGMP) to decrease the cGMP-dependent activity of protein kinase G1 (PKG1). Inhibition of PKG1 resulted in decreased phosphorylation of vasodilator-stimulated phosphoprotein (VASP), which in its hypophosphorylated state binds to and regulates F-actin assembly to facilitate cell movement. Together, these findings establish a targetable CaMKK2 – PDE1A – PKG1 – VASP signaling pathway that controls cancer cell motility and metastasis by impacting the actin cytoskeleton. Furthermore, it identifies CaMKK2 as a potential therapeutic target that can be exploited to restrict tumor invasiveness in patients diagnosed with early-stage TNBC or localized HGSOC. Significance: CaMKK2 regulates actin cytoskeletal dynamics to promote tumor invasiveness and can be inhibited to suppress metastasis of breast and ovarian cancer, indicating CaMKK2 inhibition as a therapeutic strategy to arrest disease progression.
Year:
2025
Purpose: Sensitivity to endocrine therapy (ET) is critical for the clinical benefit from the combination of palbociclib plus ET in hormone receptor–positive/HER2-negative (HR + /HER2 − ) advanced breast cancer. Bazedoxifene is a third-generation selective estrogen receptor (ER) modulator and selective ER degrader with activity in preclinical models of endocrine-resistant breast cancer, including models harboring ESR1 mutations. Clinical trials in healthy women showed that bazedoxifene is well tolerated. Patients and Methods: We conducted a phase Ib/II study of bazedoxifene plus palbociclib in patients with HR + /HER2 − advanced breast cancer who progressed on prior ET ( N = 36; NCT02448771). Results: The study met its primary endpoint, with a clinical benefit rate of 33.3%, and the safety profile was consistent with what has previously been seen with palbociclib monotherapy. The median progression-free survival (PFS) was 3.6 months [95% confidence interval (CI), 2.0–7.2]. An activating PIK3CA mutation at baseline was associated with a shorter PFS (HR = 4.4; 95% CI, 1.5–13; P = 0.0026), but activating ESR1 mutations did not impact the PFS. Longitudinal plasma circulating tumor DNA whole-exome sequencing (WES; N = 68 plasma samples) provided an overview of the tumor heterogeneity and the subclonal genetic evolution, and identified actionable mutations acquired during treatment. Conclusions: The combination of palbociclib and bazedoxifene has clinical efficacy and an acceptable safety profile in a heavily pretreated patient population with advanced HR + /HER2 − breast cancer. These results merit continued investigation of bazedoxifene in breast cancer.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (27)
Andrew Armstrong
Professor
Duke Cancer Institute
Ann Marie Pendergast
Professor and Vice Chair
Duke University
Vivek Arora
Assistant Professor
Washington University in Saint Louis School of Medicine
Charles Perou
Professor
University of North Carolina
Kris Wood
Assistant/Associate/Full Professor (with tenure)
Duke University
Raju Kandimalla
Research Associate
Baylor University Medical Center
Matthew E. Burow
Tulane University School of Medicine
Susan Dent
Medical Oncologist
University of Rochester
Daniel J. George
Professor
Duke University
Susan Halabi
Duke University
Frank H. Lau
Professor
Louisiana State University Health Sciences Center
Ruth A Keri
Case Western Reserve University
Suzanne Wardell
Assistant Professor
Duke University
Hung-Ying Kao
Full Professor
Case Western Reserve University School of Medicine
Sichun Yang
Professor with Tenure
Case Western Reserve University
Kyle Strickland
Assistant Professor
Duke Medicine
Rebecca Previs
Duke University
John Norris
Associate Research Professor
Duke University
Emmanuel S. Antonarakis
-
Gad Getz
Broad Institute
Russell Z. Szmulewitz
Associate Professor
University of Chicago
Tim Coorens
Research Group Leader
European Bioinformatics Institute
David Nanus
Professor of Medicine
Weill Cornell Medicine
Li-Sheng Geng
Professor of Physics
Beihang University
Eric Winer
Director
Yale University
sandeep artham
Duke University
Siyuan Guo
Assistant Professor
Virginia Commonwealth University
Make your next move.
Prepare your application
Review drafts before you send them.